Wissenschaftliche Publikationen Martin Aringer

Wissenschaftliche Publikationen Martin Aringer



Originalarbeiten (Kumulativer Impact-Faktor 315,164, Erstautor 52,094)


1.      Aringer M, Wintersberger W, Steiner CW, Kiener H, Presterl E, Jaeger U, Smolen JS, Graninger WB. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1423-1430. Impact factor 6,787.

2.      Kiener H, Graninger W, Machold K, Aringer M, Graninger WB. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 1994; 12: 483-487. Impact factor 2,364.

3.      Jilma B, Eichler HG, Breiteneder H, Wolzt M, Aringer M, Graninger W, Rohrer C, Veitl M, Wagner OF. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 1994; 79: 1619-1624. Impact factor 6,325. 

4.      Erlacher L, Maier R, Ullrich R, Kiener H, Aringer M, Menschik M, Graninger W. Differential expression of the protooncogene bcl-2 in normal and osteoarthritic human articular cartilage. J Rheumatol 1995; 22: 926-931. Impact factor 3,282.

5.      Seidl G, Ullrich R, Trattnig S, Dominkus M, Morscher M, Aringer M, Imhof H. MR imaging in gout. Radiologe 1996; 36: 632-636. Impact factor 0,531.

6.      Aringer M, Graninger WB, Smolen JS, Kiener HP, Steiner CW, Trautinger F, Knobler. R. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br J Rheumatol 1997; 36: 1276-1282. Impact factor 4,136.

7.      Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41: 414-420. Impact factor 6,787.

8.      Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, Graninger W. Improvement of physical fitness and muscle strength in polymyositis /dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37: 196-200. Impact factor 4,136.

9.      Aringer M, Kiener HP, Koeller MD, Artemiou O, Zuckermann A, Wieselthaler G, Klepetko W, Seidl G, Kainberger F, Bernecker P, Smolen JS, Pietschmann P. High turnover bone disease following lung transplantation. Bone 1998; 23: 485-488. Impact factor 4,145.

10. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo A-M, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA,  Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ, Kastner DL. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144. Impact factor 31,253.

11. Ebenbichler GR, Erdogmus CB, Resch KL, Funovics MA, Kainberger F, Barisani G, Aringer M, Nicolakis P, Wiesinger GF, Baghestanian M, Preisinger E, Fialka-Moser V, Weinstabl R. Ultrasound Therapy for Calcific Tendinitis of the Shoulder. N Engl J Med 1999; 340: 1533-1538. Impact factor 50,017.

12. Köller M, Aringer M, Kiener H, Erlacher L, Machold K, Eberl G, Studnicka-Benke A, Graninger W, Smolen J. Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis. Ann Rheum Dis 1999; 58: 709-712. Impact factor 7,188.

13. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O'Shea JJ. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 2000; 164: 1768-1774. Impact factor 6,000.

14. Frucht DM, Aringer M, Galon J, Danning C, Akrad M, Brown M, Centola M, Wu C-Y, Yamada N, Cheng T, Fan S, Steiner G, El-Gabalawy H, O’Shea JJ. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th-1 mediated inflammation. J Immunol 2000; 164: 4659-4664. Impact factor 6,000.

15. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O’Shea JJ, Rosenberg HF, Malech HL, Kastner DL. The gene for familial mediterranian fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95: 3223-3231. Impact factor 10,432.

16. Graninger WB, Steiner CW, Graninger MT, Aringer M, Smolen JS. Cytokine regulation of apoptosis and bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus. Cell Death Differ 2000; 7: 966-972. Impact factor 7,548.

17. Stummvoll GH, Aringer M, Köller M,  Kiener HP, Steiner CW, Bohle B, Knobler R, Smolen JS, Graninger WB. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 2000; 39: 1341-1350. Impact factor 4,136.

18. Aringer M, Stummvoll GH, Steiner G, Hiesberger H, Smolen JS, Graninger WB. Serum Interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 2001; 40: 876-881. Impact factor 4,136.

19. Aringer M, Feierl E, Steiner G, Stummvoll GH, Höfler E, Steiner CW, Radda I, Smolen JS, Graninger WB. Increased bioactive TNF in human systemic lupus erythematosus - associations with cell death. Lupus 2002; 11: 102-108. Impact factor 2,393.

20. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29: 1430- 1436. Impact factor 3,317.

21. Köller MD, Kiener HP, Aringer M, Graninger WB, Meuer S, Samstag Y, Smolen JS. Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency. Clin Exp Immunol 2003; 132: 225-231. Impact factor 2,853.

22. Aringer M, Hofmann SR, Frucht DM, Chen M, Centola M, Morinobu A, Visconti R, Kastner DL, Smolen JS, O’Shea JJ. Characterization and analysis of the proximal Jak3 promoter. J Immunol 2003; 170: 6057-6064. Impact factor 6,000.

23. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, Graninger WB. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004; 63: 569-574. Impact factor 7,188.

24. Pawelec G, Mariani E, McLeod J, Ben-Yehuda A, Fülöp T, Aringer M, Barnett Y.  Engineering anticancer T cells for extended functional longevity. Ann NY Acad Sci 2004; 1019: 178-185. Impact factor 2,303.

25. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004; 50: 3161-3169. Impact factor 6,787.

26. Grisar JC, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut B, Wagner L, Pietschmann P, Smolen JS. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004; 63: 1632-1637. Impact factor 7,188.

27. Stummvoll GH, Aringer M, Jansen M, Smolen J, Derfler K, Graninger W. Immuno-adsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 2004; 116: 716-724. Impact factor 0,857.

28. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jimenez-Boj E, Hörl WH, Graninger WB, Derfler K. IgG immunoadsorption (IAS) reduces SLE activity and proteinuria - a long term observational study. Ann Rheum Dis 2005; 64: 1015-1021. Impact factor 7,188.

29. Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279. Impact factor 6,787.

30. Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66: 966-969. Impact factor 7,188.

31. Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007; 62: 437-442. Impact factor 2,339.

32. Feierl E, Smolen JS, Karonitsch T, Stummvoll GH, Ekhart H, Steiner CW, Aringer M. Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon. Autoimmunity 2007; 40: 315-321. Impact factor 2,525.

33. Stamm TA, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G, Smolen JS, Machold KP, Aringer M. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007: 57: 1287-1295. Impact factor 6,787.

34. Rozman B, Euènik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkoviæ B, Stankoviæ A, Kveder T. Prevalence and clinical associations of anti-KU antibodies in patients with systemic sclerosis: a European EUSTAR - initiated multicentre case-control study. Ann Rheum Dis 2008; 67: 1282-1286. Impact factor 7,188.

35. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442. Impact factor 30,259.

36. Stummvoll GH, Fritsch RD, Meyer B, Hoefler E, Aringer M, Smolen JS, Steiner G. Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythematosus. Ann Rheum Dis 2008; 68: 110-116. Impact factor 7,188.

37. Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum 2008; 58: 1226-1236. Impact factor 6,787.

38. Bauernfeind B, Aringer M, Prodinger B, Kirchberger I, Machold K, Smolen J, Stamm T. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum 2009; 61: 21-8. Impact factor 6,787.

39. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alén J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, O'Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, Hughes G. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263. Impact factor 2,244.

40.   Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, Rapp A, Steiner G, Scheinecker C, Smolen J, Aringer M. Activation of the Interferon-gamma Signaling Pathway in SLE Peripheral Blood Mononuclear Cells. Arthritis Rheum 2009; 60: 1463-1471. Impact factor 6,787.

41.   Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-1454. Impact factor 4,136.

42.   Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis 2009 Nov 5. [Epub ahead of print] Impact factor 7,188.



Case Reports (Kumulativer Impact-Faktor 16,388, Erstautor 0,857)


1.      Aringer M, Pirich C, Wenger S, Kiener HP, Machold K, Stanek G, Graninger WB. A case of Lyme borreliosis with arthritis and a cardiac conduction defect. Wien Med Wschr 1995; 145: 195-196.

2.      Koeller M, Kiener H, Simonitsch I, Aringer M, Steiner CW, Machold K, Graninger W. Destructive lymphadenopathy and T-lymphocyte activation in adult-onset Still's disease. Br J Rheumatol 1995; 34: 984-988. Impact factor 4,136.

3.      Aringer M, Vierhapper H, Graninger MT, Bernecker P, Smolen JS, Pietschmann P. Successful therapy of high turnover osteoporosis in a patient with adrenocortical insufficiency. Wien Klin Wochenschr 2000; 112: 334-337. Impact factor 0,857.

4.      Stummvoll GH, Aringer M, Machold KP, Smolen JS, Raderer M. Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. Scand J Rheumatol; 2001; 30: 40-44. Impact factor 2,345.

5.      Schett G, Herak P, Graninger W, Smolen JS, Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature.
J Clin Microbiol 2005; 43: 2537-2541.
Impact factor 3,945.

6.      Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C, Wozel G. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 2008; 121: e3-4. Impact factor 5,105.


Wissenschaftliche Reviews/ Editorials (Kumulativer Impact-Faktor 83,415, Erstautor 61,740)


1.      Aringer M, Cheng A, Nelson JW, Chen M, Sudarshan C, Zhou Y-J, O’Shea JJ. Janus kinases and their role in growth and disease. Life Sciences 1999; 64: 2173-2186. Impact factor 2,583.

2.      Aringer M, Frucht DM, O’Shea JJ. Interleukin/Interferon signaling: A 1999 perspective. Immunologist 1999; 7: 139-146.

3.      Aringer M. T lymphocyte activation – an inside overview. Acta Med Austriaca 2002; 29: 7-13. Impact factor 0,346.

4.      Aringer M, Smolen JS. Complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor (TNF) in SLE. Arthritis Res Ther 2003; 5: 172-177. Impact factor 4,485.

5.      Elewaut D, Aringer M, Muller-Ladner U. Getting scientists together: the ACR/EULAR exchange programme. Ann Rheum Dis 2003; 62: 789-90. Impact factor 7,188.

6.      Aringer M. Periodic fever syndromes – a clinical overview. Acta Med Austriaca 2004; 31(1): 8-12. Impact factor 0,346.

7.      Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13: 344-347. Impact factor 2,244.

8.      Aringer M, Smolen JS. Cytokine expression in lupus kidney. Lupus 2005; 14: 13-18. Impact factor 2,244.

9.      Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005; 14: 189-191. Impact factor 2,244.

10. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005; 31: 411-20. Impact factor 1,770.

11. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005; 19: 859-78. Impact factor 3,066.

12. Aringer M, Smolen JS. Systemic lupus erythematosus - activity and outcome. Z Rheumatol 2006; 65: 103-109. Impact factor 0,533.

13. Aringer M, Stamm TA, Pisetsky DS, Yarboro CH, Cieza A, Smolen JS, Stucki G. ICF Core Sets: How To Specify Impairment and Function in SLE. Lupus 2006; 15: 248-253. Impact factor 2,244.

14. Winzer M, Gräßler J, Aringer M. Crystal-induced arthritis - old but important. Z Rheumatol 2007; 66: 317-325. Impact factor 0,533.

15. Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Gräßler J. Molecular basis of primary renal hyperuricemia: Role of the human urate transporter hURAT1. Z Rheumatol 2007; 66: 556-561. Impact factor 0,533.

16. Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: S4-11. Impact factor 2,364.

17. Aringer M, Leuchten N, Machold KP. Early rheumatoid arthritis - rapid help is double help. Z Rheumatol 2007; 66: 693-702. Impact factor 0,533.

18. Aringer M, Smolen JS. Mixed connective tissue disease: what is behind the curtain? Best Pract Res Clin Rheumatol 2007; 21: 1037-49. Impact factor 3,066.

19. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008 Jan 23; 10: 202 (Epub ahead of print) Impact factor 4,035.

20. Aringer M, Feierl E, Smolen J. Cytokine blockade - a promising therapeutic option in SLE. Z Rheumatol. 2008 May 21. [Epub ahead of print] Impact factor 0,533.

21. Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008; 7: 411-9. Impact Factor 3,073.

22. Aringer M, Crow MK. A Bridge Between Interferon-alpha and Tumor Necrosis Factor in Lupus. J Rheumatol 2008 Aug; 35: 1473-6. Impact Factor 3,282.

23. Aringer M, Graessler J. Understanding deficient elimination of uric acid. Lancet 2008; 372: 1929-30. Impact Factor 27,264.

24. Leuchten N, Aringer M. Rheumatoid arthritis today. Internist (Berl) 2008; 49: 1471-82. Impact factor 0,464.

25. Aringer M, Smolen J. TNF inhibition in SLE: where do we stand? Lupus 2009; 18: 5-8. Impact factor 2,244.

26. Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U. Gout-current diagnosis and treatment. Dtsch Arztebl Int 2009; 106: 549-555.

27. Winzer M, Tausche AK, Aringer M. Crystal-induced activation of the inflammasome: gout and pseudogout. Z Rheumatol 2009; 68: 733-739. Impact factor 0,533.

28. Stummvoll GH, Julius U, Derfler K, Aringer M. Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 2009; 10: 110-113. Impact Factor 4,601.

29. Aringer M, Smolen JS. Therapeutic blockade of TNF in SLE – promising or crazy? Autoimm Rev 2010 in press.




1.      Aringer M, Steiner G, Graninger W, Smolen J. Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. Arthritis Rheum 2001; 44:1721-1722.

2.      Hermann J, Muller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P, Graninger W. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. Ann Rheum Dis 2007; 66: 561-562.




1.      Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007.

2.      Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009.




1.      Aringer M, Watford W, O’Shea JJ. Stats and Jaks. In Smolen JS, Lipsky PE, eds.: Targeted therapies in rheumatology. Martin Dunitz London, New York 2003; 403-420.

2.      Emminger W, Aringer M. Juvenile rheumatoide Arthritis. In Müller-Ladner U, Hrsg: EvidenzbasierteTherapie in der Rheumatologie. Uni-Med Bremen, London, Boston 2005; 56-68.

3.      Aringer M, Redlich K. Cyclophosphamid. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 34-37.

4.      Dörner T, Aringer M. Immunadsorption und Biologicals. In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 48-52.

5.      Hiepe F, Aringer M. Basistherapie des nicht-renalen SLE – was ist gesichert? In Aringer M, Hrsg: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Uni-Med Bremen, London, Boston 2007; 54-56.

6.      Aringer M. Rezeptoren und Signalltransduktion – ein kurzer Überblick. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 12-15.

7.      Tausche AK, Aringer M. Infliximab, Etanercept, Adalimumab (und Golimumab): TNF-Blocker im Vergleich. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 18-22.

8.      Winzer M, Aringer M. Interleukin-6-Rezeptor-Blockade. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 40-43.

9.      Leuchten N, Aringer M. Interleukin-15-Blockade. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 46-48.

10. Kleyman O, Aringer M. Interleukin-18-Blockade. In Aringer M, Hrsg: Antizytokintherapie der rheumatoiden Arthritis. Uni-Med Bremen, London, Boston 2009; 56-57.

nach oben